Boston Scientific Corporation $BSX Holdings Lifted by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 23.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 200,649 shares of the medical equipment provider’s stock after acquiring an additional 37,784 shares during the period. J. Safra Sarasin Holding AG’s holdings in Boston Scientific were worth $21,552,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Lecap Asset Management Ltd. acquired a new position in shares of Boston Scientific in the 2nd quarter worth approximately $2,908,000. ASR Vermogensbeheer N.V. boosted its holdings in Boston Scientific by 0.4% during the second quarter. ASR Vermogensbeheer N.V. now owns 454,047 shares of the medical equipment provider’s stock worth $48,768,000 after buying an additional 1,770 shares in the last quarter. Consolidated Planning Corp grew its position in Boston Scientific by 2.3% in the second quarter. Consolidated Planning Corp now owns 50,313 shares of the medical equipment provider’s stock worth $5,404,000 after buying an additional 1,133 shares during the last quarter. Robeco Institutional Asset Management B.V. increased its holdings in shares of Boston Scientific by 31.6% in the second quarter. Robeco Institutional Asset Management B.V. now owns 3,145,777 shares of the medical equipment provider’s stock valued at $337,888,000 after buying an additional 756,199 shares in the last quarter. Finally, BSW Wealth Partners lifted its position in shares of Boston Scientific by 2.2% during the 2nd quarter. BSW Wealth Partners now owns 8,667 shares of the medical equipment provider’s stock valued at $931,000 after acquiring an additional 188 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Trading Up 0.5%

NYSE BSX opened at $96.36 on Friday. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50. The firm’s fifty day simple moving average is $103.10 and its 200-day simple moving average is $102.06. The company has a market capitalization of $142.78 billion, a PE ratio of 57.36, a price-to-earnings-growth ratio of 2.31 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the previous year, the company posted $0.62 earnings per share. The business’s quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of recent research reports. Wells Fargo & Company lifted their target price on Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a report on Thursday, July 24th. Raymond James Financial lifted their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 24th. Barclays upped their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday. UBS Group lifted their target price on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, July 24th. Finally, Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $118.00 to $125.00 in a report on Monday, September 8th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $120.79.

Insider Transactions at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $18,659,923.46. This trade represents a 21.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares of the company’s stock, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 174,214 shares of company stock worth $17,972,457. Corporate insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.